Cargando…
Novel specific anti‐ESM1 antibodies overcome tumor bevacizumab resistance by suppressing angiogenesis and metastasis
Suppressing tumors through anti‐angiogenesis has been established as an effective clinical treatment strategy. Bevacizumab, a monoclonal antibody, is commonly used in various indications. However, two major challenges limit the long‐term efficacy of bevacizumab: drug resistance and side effects. Bev...
Autores principales: | Kang, Nannan, Fan, Buxi, Sun, Yao, Xue, Peilin, Liu, Yu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637069/ https://www.ncbi.nlm.nih.gov/pubmed/37715566 http://dx.doi.org/10.1111/cas.15939 |
Ejemplares similares
-
Endothelial-Specific Molecule 1 Inhibition Lessens Productive Angiogenesis and Tumor Metastasis to Overcome Bevacizumab Resistance
por: Kang, Nannan, et al.
Publicado: (2022) -
Practical ESM analysis
por: Robertson, Sue
Publicado: (2019) -
Targeting ESM1/ VEGFα signaling axis: a promising therapeutic avenue for angiogenesis in cervical squamous cell carcinoma
por: Li, Dan, et al.
Publicado: (2023) -
ESM1 mediates NGFR-induced invasion and metastasis in murine oral squamous cell carcinoma
por: Chen, Chen, et al.
Publicado: (2016) -
HULC long noncoding RNA silencing suppresses angiogenesis by regulating ESM-1 via the PI3K/Akt/mTOR signaling pathway in human gliomas
por: Zhu, Yu, et al.
Publicado: (2016)